Press release from PR Newswire
Hologic to Release Third Quarter Fiscal 2012 Operating Results on Monday, July 30, 2012
Monday, June 25, 2012
Hologic to Release Third Quarter Fiscal 2012 Operating Results on Monday, July 30, 201207:00 EDT Monday, June 25, 2012BEDFORD, Mass., June 25, 2012 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced plans to release its third quarter fiscal 2012 operating results on Monday, July 30, 2012 after market close. In conjunction with the release, management will host a conference call on Monday, July 30, 2012, at 5:00 p.m. (eastern).Interested participants may listen to the call by dialing 888-349-9582 or 719-325-2182 for international callers and referencing code 3813469 approximately 15 minutes prior to the call on July 30th. For those unable to participate in the live broadcast, a replay will be available one hour after the call ends through Friday, August 17, 2012, at 888-203-1112 or 719-457-0820 for international callers, access code 3813469.The Company will also provide a live webcast of the call. Interested participants may access the webcast on the Company's website at www.hologic.com/investors-overview. A replay of the call will be archived on the Company's website and a PowerPoint presentation related to the conference call will be posted to the site after market close on Monday, July 30, 2012.About Hologic, Inc. Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, breast magnetic resonance imaging, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia and uterine fibroids, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including reagents for a variety of DNA and RNA analysis applications. For more information, visit www.hologic.com.Contact: Deborah R. GordonVice President, Investor RelationsHologic, Inc.(781) 999-7716 SOURCE Hologic, Inc.